Minerva Q1 GAAP net loss $125.4M on warrant revaluation; Phase 3 roluperidone trial advances

Minerva Neurosciences, Inc.

2026-Q1 EPS reported -$2.86

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated; first patient screened March 2026; topline data expected 2H 2027.
GAAP net loss $125.4M ($2.86/share) vs $3.8M ($0.50) prior year; non-GAAP adjusted net loss $7.3M ($0.17/share).
Cash and equivalents $78.2M at March 31, down from $82.4M at Dec 31; warrant exercise raised net $1.2M in Q1.
Leadership: Appointed Jim O’Connor CBO & General Counsel; President Geoff Race left, remains as consultant.
R&D spend rose to $5.3M from $1.4M on trial costs; G&A $11.4M included $6.6M one-time stock comp charge.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Minerva Neurosciences, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $125.4 million, or $2.86 per basic and diluted share, EPS $2.86 per basic and diluted share.

Period: first quarter ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026 was $125.4 million, or $2.86 per basic and diluted share
EPS: $2.86 per basic and diluted share
Result: reported results

Exact text from the filing

today reported financial and business updates for the first quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Minerva Neurosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-205129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.